Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 174

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 174
---
 a material level of judgment and if changes in those judgments are reasonably likely to materially impact
our results.

We base our estimates and judgments on reasonably available information. Our estimates and assumptions may affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates and such differences
may be material to the financial statements.

We continue to monitor and assess our critical estimates in light of developments, and as new events occur and
additional information is obtained, our estimates may change materially in future periods.

Revenue

We generate revenue primarily from our prenatal and oncology testing services, which are referred to as testing services or test results. We consider the patient as our
customer, that requests our test service through their physician. Test results are the single performance obligation being provided to customers. Testing service revenue is recognized at a point in time when test results are delivered to the
ordering physician. We generally bill an insurance carrier, Medicaid or a patient or a combination of both upon delivery of test results. test results. The amount of revenue recognized reflects the consideration we expect to be entitled to receive
in exchange for the test results.

We recognize revenue upon transfer of control of promised goods and services in an amount that reflects the consideration we
expect to be entitled to receive in exchange for those goods and services. Under ASC 606, Revenue from Contracts with Customers (ASC 606), we apply the following five-step approach: (1) identify the contract with a customer, (2) identify
the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when, or as, a performance obligation is
satisfied.

We recognize revenue applying estimated consideration to be received for the performance obligations delivered to customers and their representatives. In
accordance with ASC 606, we apply the constraint on variable consideration and include such amounts in the transaction price only to the extent that it is probable that a significant reversal of cumulative revenue will not occur when the associated
uncertainty is resolved.

117

We apply the expected value method of estimating variable consideration. The total consideration we expect to collect in exchange for our products is an estimate and is largely variable in nature. Consideration includes reimbursement from both patients and insurance carriers. We establish variable consideration by considering historical payment trends for tests delivered, test reimbursement disallowances,